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enters the A site of the ribosome and forms an amide tained from a hybrid library of approximately a trillion
bond with the translated peptide. The result is a stable different peptide-drug conjugates. In addition to provid-
mRNA/DNA/peptide hybrid in which the translated pep- ing significant technological advances over the phage
tide is physically attached to the RNA from which it was display and standard mRNA display library protocols
translated and can, in turn, be amplified by PCR between described, the hybrid library has generated inhibitors to
rounds of peptide selection. PBP2a that could be useful for overcoming -lactam
Peptide-small molecule hybrid libraries could be con- resistance in methicillin-resistant S. aureus.
ceived in two ways. One possibility is that the hybrid The results presented by Li and Roberts may be most
library centers on a small lead molecule which is com- memorable for their promise of harnessing the vast di-
bined with a very large number of peptide appendages. versities of peptide/small molecules in a library format
The alternative is that a large peptide library is produced rather than for the specific achievement of tethering
containing combinations of the normal complement of penicillin to a peptide library. By appending the peptide
20 proteinogenic amino acids plus a noncoded residue/ to a site on penicillin known to tolerate (and benefit from)
small molecule. Roberts previously reported the prepa- additional functionality, the results of the experiment
ration of peptide libraries containing noncoded amino are perhaps not too surprising. The two researchers
acids (the equivalent of the small molecule in the present argue convincingly that the modest affinities achieved
report) that were prepared by suppression mutagenesis in their experiment are not indicative of the actual im-
[6]. This technique requires a substantial synthetic effort provement gained from the tethered peptide, and that
in the preparation of the requisite suppressor tRNA, and it is the 100-fold increase in affinity that demonstrates
furthermore, it is perhaps not generally recognized that the value of their technique. Regardless, this experiment
the efficiency of the suppression itself, i.e., introduction builds a bridge to a new frontier of peptide-small mole-
of the noncoded amino acid via “reading” of a stop cule hybrid libraries that holds far-reaching and exciting
codon signal by the synthetic acylated tRNA, is highly possibilities for rapidly optimizing small molecule bind-
variable. This element of capriciousness makes this ing affinities without the need to synthesize large librar-
route inefficient; thus, resorting to a more traditional ies of small molecules.
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tive uptake inhibitors holds promise for mechanistic
studies of SR-BI and for discovery of pharmaceuticals
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Selecting Selective Suppressors
of Selective Uptake useful in therapy of atherosclerosis.
The selective uptake of HDL CE is a major pathway by
which plasma HDL cholesterol is delivered to the liverScavenger receptor BI (SR-BI) is a high-density lipo-
protein (HDL) receptor that mediates the selective up- and steroidogenic cells [1–3]. In contrast to the LDL
receptor pathway in which LDL particles are endocy-take of HDL cholesteryl ester (CE) and the bidirectional
flux of free cholesterol (FC). The identification of selec- tosed and degraded in cells to release cholesterol [4],
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HDL-selective uptake involves the transfer of HDL CE BI-mediated pathways in man. If BLTs are active in vivo
to the plasma membrane without HDL uptake and degra- in other species, it will permit a simpler assessment of
dation [5, 6]. The discovery of SR-BI as the cell surface SR-BI function in many species not amenable to the
receptor that mediates HDL CE-selective uptake [7] was genetic targeting strategies used in mice. This is particu-
followed quickly by the finding that SR-BI also stimu- larly true in nonhuman primates that provide the best
lates the bidirectional flux of FC between HDL and cells models for human lipoprotein metabolism and coronary
[8]. Studies with SR-BI knockout mice and mice engi- artery disease [24]. Information from such studies may
neered to overexpress SR-BI demonstrated that SR-BI be particularly useful in determining whether pharma-
is a key determinant of plasma HDL concentration and ceutical elevation of SR-BI activity will be therapeutically
the hepatic uptake and transfer of HDL cholesterol to useful in man. The BLTs may also accelerate studies in
bile, the major pathway by which cholesterol is elimi- gene-targeted mice. Krieger and colleagues, for exam-
nated from the body [9–12]. Further studies in mice show ple, found that the SR-BI/apoE double knockout mouse
that this HDL receptor is protective against the develop- shows unexpectedly accelerated and exacerbated ath-
ment of atherosclerosis [10, 13–16]. As a key player in erosclerosis compared to the atherosclerosis-suscepti-
the metabolism of the “good” cholesterol, SR-BI has ble apoE knockout mouse [15], and even shows coro-
been the subject of intense study in academic and phar- nary artery lesions and myocardial infarctions [25],
maceutical laboratories. features not typically observed in mice. Such studies
In a recent report, Nieland et al. used a high often reveal phenotypes due to unrecognized interac-
throughput screen based on the uptake of a fluorescent tions between atherosclerosis susceptibility genes but
lipid from HDL to identify small molecule inhibitors of require lengthy animal breeding to combine different
SR-BI [17]. Of the inhibitors, designated blocking lipid targeted genes. BLTs may facilitate rapid evaluations
transport (BLT) 1–5, three appear structurally dissimilar of the importance of SR-BI in HDL metabolism and ath-
from two others. All are hydrophobic and contain O and erosclerosis in other gene-targeted models by chemi-
N atoms that could participate in hydrogen bonding with cally creating SR-BI deficiency.
amino acid side chains. Structure-activity studies are The BLT’s should prove useful in studies of SR-BI effects
warranted to define chemical features important for SR- on cellular cholesterol metabolism where SR-BI shows
BI inhibition. a variety of apparently distinct effects. SR-BI enhances
One surprise from their results is that the BLTs do not FC efflux to nonphysiological cyclodextrin acceptors by
disrupt SR-BI-mediated lipid transport by blocking HDL increasing the size of the fast kinetic pool of membrane
binding. In fact, the BLTs modestly increase the binding FC [26]. Additionally, SR-BI-mediated FC efflux to small
affinity of SR-BI for HDL, in part by decreasing the HDL unilamellar vesicles (SUV) composed of neutral or acidic
dissociation rate. In addition to blocking selective lipid phospholipids is equivalent [19] despite the fact that
uptake, BLTs inhibit SR-BI-mediated efflux of FC from acidic SUV bind to SR-BI with high affinity and neutral
cells to HDL. This result may indicate a common path- SUV bind poorly if at all [27]. SR-BI also increases the
way for transfer of CE and FC between cells and HDL. fraction of plasma membrane FC that is sensitive to
Early studies led to the hypothesis that SR-BI provides a oxidation by exogenous cholesterol oxidase, suggesting
hydrophobic channel along which CE molecules diffuse an altered organization of FC in the membrane [19]. These
down a concentration gradient from the HDL particle to data suggest that one component of SR-BI-mediated FC
the plasma membrane [18]. SR-BI-mediated net transfer flux occurs independently of HDL and involves changes
of FC to and from HDL also depends on the FC concen- in the plasma membrane that facilitate FC desorption.
tration gradient between the cell and the HDL particle Several findings also support a key role for HDL binding
[19, 20]. One way in which these inhibitors may act is
to SR-BI [21, 28]. Taken together, these data support a
by occupying the hydrophobic channel to impede the
model of SR-BI-mediated FC efflux that involves two
movement of FC and CE. Another possibility is that
components. One, as exemplified by the SR-BI muta-
BLTs, although they do not inhibit HDL binding, may
tions [21, 28], requires HDL binding to SR-BI. The other,alter the proper alignment of the HDL/SR-BI complex.
as exemplified by FC efflux to cyclodextrins and neutralHigh-affinity binding of HDL to SR-BI is not in itself
SUV [19, 26], involves SR-BI-mediated changes in thesufficient for efficient lipid transfer; presumably, apoA-I,
plasma membrane. The BLTs may prove useful in under-the major HDL protein, must assume a correct confor-
standing these components and their quantitative im-mation on the HDL surface to interact productively with
portance in overall FC flux between cells and HDL.SR-BI to promote efficient lipid transfer [21, 22]. A re-
Perhaps the most striking feature of the study by Nie-cently described system in which SR-BI is reconstituted
land and colleagues [17] is the proof of principle that ainto membrane vesicles should prove useful for testing
cell-based, high throughput screen is capable of identi-whether BLTs bind directly to SR-BI [23].
fying molecules that modulate a process important forThe BLTs should be useful in a number of arenas. For
the regulation of plasma cholesterol by the liver in vivo.example, we know a lot about HDL CE-selective uptake
Screening of additional chemical libraries may uncoverin the rodent but much less in other species, including
agents that enhance SR-BI activity and have therapeuticman, that express cholesteryl ester transfer protein
potential to increase reverse cholesterol transport, the(CETP). CETP moves CE from HDL to VLDL and LDL,
overall movement of cholesterol from peripheral cellspermitting CE removal from the plasma via the LDL re-
to the liver. Similar screens could be used with the LDLceptor pathway [4]. CETP makes kinetic studies of HDL
receptor to identify agents that act in this pathway butCE clearance from plasma difficult and has held back
our understanding of the quantitative importance of SR- at a different level than the popular statin drugs.
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[1]. TTS systems function in many cases only when the
pathogen is intimately associated with a host cell. In this
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Disarming the Invader
context, the physical interaction between the bacterium
and the host cell induces the TTS system to deliver
virulence proteins in a single step from the bacterialType III secretion systems are used by many gram-
cytosol into the cytosol of the cell. This is a remarkablenegative bacterial pathogens of animals and plants to
task when one considers that the delivery of proteins bydeliver essential virulence factors into targeted host
gram-negative bacteria into a eukaryotic cell demandscells. The identification of chemical compounds that
transport across three biological membranes. The par-block the function of these systems is the first step
ticular set of proteins delivered by different pathogens istoward developing chemical attenuation as an effec-
highly divergent, but the bacterial machinery composingtive method for the treatment of infectious disease.
the TTS systems is quite conserved. Thus, many gram-
negative bacteria that cause disease have in commonOver the past decade it has become abundantly clear
TTS systems, which can be targeted for the develop-that despite vastly different disease outcomes caused
ment of chemical compounds to block an essential viru-by pathogenic bacteria, common mechanisms exist for
lence activity and effectively disarm this group of bacte-targeting specific virulence factors to host sites. Type
rial invaders.III secretion (TTS) systems are essential for virulence
While TTS systems are required for survival of bacteriaof many gram-negative pathogens of animals including
during infection, they are dispensable for bacteria thatspecies of Bordetella, Chlamydia, Pseudomonas, Sal-
have a free-living stage in their life cycle. Thus, a com-monella, Shigella, and Yersinia [1]. In humans, these
pound that blocks TTS will not necessarily inhibit bacte-bacteria cause a variety of diseases such as whooping
rial growth. Traditionally, antibiotics are developed tocough, plague, and several forms of gastroenteritis.
interfere with an activity, such as synthesis of DNA,Moreover, several plant diseases, which have had great
RNA, peptidoglycans, or proteins, which is essential foreconomic impact, are caused by bacteria that utilize TTS
bacterial growth or survival [2]. This approach has beensystems such as Erwinia spp., Pseudomonas syringae,
Ralstonia solanacearum, and Xanthomonas campestris very productive and has changed the fate of humanity
